Loading...

Swedish Orphan Biovitrum AB (publ)

BIOVF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$47.48
$0.13(0.27%)
U.S. Market opens in 7h 38m

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Overview

Explore Swedish Orphan Biovitrum AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap16.4B
P/E Ratio162.45
EPS (TTM)$0.28
ROE0.02%
Fundamental Analysis

AI Price Forecasts

1 Month$35.69
3 Months$36.96
1 Year Target$36.11

BIOVF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Swedish Orphan Biovitrum AB (publ) (BIOVF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 96.11, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $36.11.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 162.45 and a market capitalization of 16.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
0.26%
5-Day Change
10.02%
1-Month Change
19.07%
3-Month Change
28.31%
6-Month Change
36.11%
Year-to-Date (YTD) Change
34.68%
1-Year Change
55.66%
3-Year Change
116.88%
5-Year Change
211.52%
All-Time (Max) Change
145.60%

Contact Information

https://www.sobi.com
46 86 97 20 00
Tomtebodavägen 23A, Solna, NaN, 112 76

Company Facts

1,895 Employees
IPO DateJan 8, 2021
CountrySE
Actively Trading

Frequently Asked Questions